^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

INGN 225

i
Other names: INGN 225, Ad.p53 DC vaccine, adenovirus-p53 transduced dendritic cell vaccine, autologous dendritic cell adenovirus p53 vaccine, INGN-225
Associations
Company:
Lumos Pharma
Drug class:
p53 stimulant
Associations
over1year
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
P2, N=14, Terminated, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2023 --> May 2022 | Active, not recruiting --> Terminated; Sponsor closed study
Trial completion date • Trial termination
|
TP53 (Tumor protein P53)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • INGN 225
over2years
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
P2, N=14, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Apr 2022 --> Dec 2022
Trial primary completion date
|
TP53 (Tumor protein P53) • IFNG (Interferon, gamma)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • INGN 225
almost3years
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
P2, N=14, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Dec 2021 --> Apr 2022
Clinical • Trial primary completion date
|
TP53 (Tumor protein P53) • IFNG (Interferon, gamma)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • INGN 225
over3years
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
P2, N=14, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Apr 2024 --> Dec 2023 | Trial primary completion date: Apr 2022 --> Dec 2021
Clinical • Trial completion date • Trial primary completion date
|
TP53 (Tumor protein P53) • IFNG (Interferon, gamma)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • INGN 225